Furthermore, we evaluated the therapeutic efficacy of CX-4945 using ESCC patient-derived xenograft (PDX) mouse models derived from LEG379, LEG397, and LEG460 cases with relatively elevated or moderate p-CSNK2A1 T360/S362 levels (Supplemental Figure 8, D and E). This evidence concerns the gene CSNK2A1 and esophageal squamous cell carcinoma.